Through a mechanism of AMP-independent activation, the AMPK agonist PT1 was effective in ameliorating both the energy depletion and oxidative stress associated with mitochondrial dysfunction in and strongly support the therapeutic potential of PT1 in the treatment of mitochondrial disease and other mitochondrial-related disorders. This evidence concerns the gene PRKAA1 and inborn mitochondrial metabolism disorder.